AC Immune (ACIU) Scheduled to Post Quarterly Earnings on Friday

AC Immune (NASDAQ:ACIU) is set to announce its earnings results on Friday, April 26th.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $16.71 million during the quarter, compared to analysts’ expectations of $16.36 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AC Immune Price Performance

AC Immune stock opened at $2.37 on Thursday. The firm has a 50 day simple moving average of $3.12 and a 200-day simple moving average of $3.34. AC Immune has a 1-year low of $1.78 and a 1-year high of $5.14. The stock has a market cap of $234.39 million, a price-to-earnings ratio of -3.34 and a beta of 1.00.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of AC Immune in a research note on Friday, March 15th.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.